Evidence map›Paper›PMID 28671673›Full record

ArticleOncogene2017

EWS-FLI1 perturbs MRTFB/YAP-1/TEAD target gene regulation inhibiting cytoskeletal autoregulatory feedback in Ewing sarcoma.

A M Katschnig, M O Kauer, R Schwentner, E M Tomazou, C N Mutz, M Linder, M Sibilia, J Alonso, D N T Aryee, H Kovar

Open access · hybridAbstract read
In one paragraph

Article in Oncogene, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 72 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

A M KatschnigChildren's Cancer Research Institute, St Anna Kinderkrebsforschung, Vienna, Austria.
M O KauerChildren's Cancer Research Institute, St Anna Kinderkrebsforschung, Vienna, Austria.
R SchwentnerChildren's Cancer Research Institute, St Anna Kinderkrebsforschung, Vienna, Austria.ORCID 0000-0001-6839-0322
E M TomazouChildren's Cancer Research Institute, St Anna Kinderkrebsforschung, Vienna, Austria.
C N MutzChildren's Cancer Research Institute, St Anna Kinderkrebsforschung, Vienna, Austria.
M LinderInstitute of Cancer Research, Medical University Vienna, Vienna, Austria.
M SibiliaInstitute of Cancer Research, Medical University Vienna, Vienna, Austria.
J AlonsoUnidad de Tumores Solidos Infantiles, Instituto de Investigación de Enfermedades Raras, Madrid, Spain.ORCID 0000-0002-6287-8391
D N T AryeeChildren's Cancer Research Institute, St Anna Kinderkrebsforschung, Vienna, Austria.
H KovarChildren's Cancer Research Institute, St Anna Kinderkrebsforschung, Vienna, Austria.
St Anna Children's Hospital · ATInstituto de Investigación de Enfermedades Raras · ES

Funding

Austrian Science Fund FWF V 506
6 · The paper itself

Abstract

Ewing sarcoma (EWS) is a paediatric bone cancer with high metastatic potential. Cellular plasticity resulting from dynamic cytoskeletal reorganization, typically regulated via the Rho pathway, is a prerequisite for metastasis initiation. Here, we interrogated the role of the Ewing sarcoma driver oncogene EWS-FLI1 in cytoskeletal reprogramming. We report that EWS-FLI1 strongly represses the activity of the Rho-F-actin signal pathway transcriptional effector MRTFB, affecting the expression of a large number of EWS-FLI1-anticorrelated genes including structural and regulatory cytoskeletal genes. Consistent with this finding, chromatin immunoprecipitation sequencing (ChIP-seq) revealed strong overlaps in myocardin-related transcription factor B (MRTFB) and EWS-FLI1 chromatin occupation, especially for EWS-FLI1-anticorrelated genes. Binding of the transcriptional co-activator Yes-associated protein (YAP)-1, enrichment of TEAD-binding motifs in these shared genomic binding regions and overlapping transcriptional footprints of MRTFB and TEAD factors led us to propose synergy between MRTFB and the YAP/TEAD complex in the regulation of EWS-FLI1-anticorrelated genes. We propose that EWS-FLI1 suppresses the Rho-actin pathway by perturbation of a MRTFB/YAP-1/TEAD transcriptional module, which directly affects the actin-autoregulatory feedback loop. As spontaneous fluctuations in EWS-FLI1 levels of Ewing sarcoma cells in vitro and in vivo, associated with a switch between a proliferative, non-migratory EWS-FLI1-high and a non-proliferative highly migratory EWS-FLI1-low state, were recently described, our data provide a mechanistic basis for the underlying EWS-FLI1-dependent reversible cytoskeletal reprogramming of Ewing sarcoma cells.

Indexed as

ActinsCell Line, TumorCell ProliferationCellular ReprogrammingChromatinCytoskeletonGene Expression Regulation, NeoplasticHumansOncogene Proteins, FusionProto-Oncogene Protein c-fli-1RNA-Binding Protein EWSSarcoma, EwingSignal TransductionActinsChromatinEWS-FLI fusion proteinOncogene Proteins, FusionProto-Oncogene Protein c-fli-1RNA-Binding Protein EWS

Identifiers

PMID28671673
PMCPMC5666320
OpenAlexW2725443874

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.